Galecto Appoints Anne Prener to its Board of Directors
January 08, 2021 08:00 ET
|
Galecto, Inc.
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
January 04, 2021 16:01 ET
|
Galecto, Inc.
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
December 11, 2020 08:06 ET
|
Galecto, Inc.
Successfully completed listing on US Nasdaq and raised over $150 million during recent IPO and preceding crossover round Funds to support preparations for potential EU conditional approval of GB0139...
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers
November 30, 2020 08:00 ET
|
Galecto, Inc.
The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to fall in FVCThe inhaled GB0139 significantly reduced key plasma biomarkers from baseline vs placebo over 2 weeksGB0139...
Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors
November 23, 2020 16:01 ET
|
Galecto, Inc.
Has extensive experience in pharma and biotech in U.S., Europe and globallyGalecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months BOSTON and...
Galecto Announces Pricing of Initial Public Offering
October 28, 2020 21:10 ET
|
Galecto, Inc.
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the...
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
September 25, 2020 11:41 ET
|
Galecto, Inc.
BOSTON and COPENHAGEN, Denmark, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer,...
Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase 1 Clinical Data Presented Recently at Several Scientific Conferences
September 15, 2020 08:00 ET
|
Galecto, Inc.
GB1211, a potent oral small molecule galectin-3 inhibitor was well tolerated in Phase 1 studiesPhase 2a study planned to establish the anti-fibrotic effects of GB1211 in grade 2 to 4 Non-Alcoholic...
Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis
August 27, 2020 08:00 ET
|
Galecto, Inc.
The EMA cited GB0139’s clinically relevant biomarker data in IPF patientsSignificant reduction of YKL-40 biomarker in fibrosis, inflammation, tissue remodeling diseases BOSTON and COPENHAGEN,...
Galecto Appoints New Chair and Strengthens Board of Directors
May 19, 2020 16:09 ET
|
Galecto, Inc.
Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena PharmaceuticalsSucceeds Magnus Persson, who oversaw period of rapid growth and success for GalectoAppoints David...